Astana Biomed Group, an authorized Abcam distributor in Central Asia

Anti-NAPSIN A antibody [KCG1.1] (ab73021)

Key features and details

  • Mouse monoclonal [KCG1.1] to NAPSIN A
  • Suitable for: Flow Cyt, IHC-P
  • Reacts with: Human
  • Isotype: IgG1

Overview

  • Product name

    Anti-NAPSIN A antibody [KCG1.1]
    See all NAPSIN A primary antibodies

  • Description

    Mouse monoclonal [KCG1.1] to NAPSIN A

  • Host species

    Mouse

  • Specificity

    Napsin A reactivity was determined immunohistochemically on formalin-fixed paraffin-embedded cell blocks from 50 pleural effusion (5 mesotheliomas, 10 mesothelial proliferations, 12 pulmonary, and 23 nonpulmonary metastases). Napsin A was positive in 10/12 pulmonary adenocarcinomas. The specificity of this antibody for primary lung adenocarcinoma is 47 out of 58 (81%), primary lesions were positive.

  • Tested applications

    Suitable for: Flow Cyt, IHC-Pmore details

  • Species reactivity

    Reacts with: Human

  • Immunogen

    Synthetic peptide from the N terminus of human NAPSIN A

  • Positive control

    • Lung Adenocarcinoma.

  • General notes

    Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.

    Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.

    We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.

    In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.

    We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.

    Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.

    Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.

Properties

Images

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-NAPSIN A antibody [KCG1.1] (ab73021)
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-NAPSIN A antibody [KCG1.1] (ab73021)
    ab73021, at 1 in 50 dilution, staining NAPSIN A in Human lung adenocarcinoma by Immunohistochemistry using formalin-fixed, paraffin-embedded tissue.
  • Flow Cytometry - Anti-NAPSIN A antibody [KCG1.1] (ab73021)
    Flow Cytometry - Anti-NAPSIN A antibody [KCG1.1] (ab73021)
    Overlay histogram showing A549 cells stained with ab73021 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab73021, 1/100 dilution) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in A549 cells fixed with 4% paraformaldehyde (10 min)/permeabilized with 0.1% PBS-Tween for 20 min used under the same conditions.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Alternative products to Anti-NAPSIN A antibody [KCG1.1] (ab73021)

© 2021 Astana Biomed Group LLP. All rights reserved.